For an ADHD patient with comorbid anxiety and depression who starts 20 mg of Vyvanse (lisdexamfetamine), how many days after initiating therapy should the first follow‑up appointment be scheduled?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

建议在服用20mg Vyvanse后7天内进行首次复诊

对于合并焦虑抑郁的ADHD患者开始服用20mg Vyvanse后，应在1周内进行首次随访评估，此后在剂量调整期间保持每周联系（可通过电话），直到症状稳定后改为至少每月随访。 由于患者存在共病精神障碍，需要更频繁的监测。

初始滴定期的随访时间表

根据美国儿童青少年精神病学会的实践指南，兴奋剂治疗的初始滴定阶段需要密切监测1:

  • 第1周：首次随访应在开始用药后1周内进行，评估ADHD核心症状的改善情况和副作用
  • 第2-4周：在剂量调整期间，每周保持联系（可通过电话或门诊）1
  • 滴定期通常需要2-4周来完成剂量调整1

合并焦虑抑郁患者的特殊考虑

由于患者合并焦虑和抑郁，需要更频繁的随访1:

  • 指南明确指出："当存在副作用、共病精神障碍导致的显著功能损害时，应安排更频繁的随访"1
  • 对于合并焦虑抑郁的ADHD患者，应先进行兴奋剂试验，因为ADHD症状的改善可能对抑郁症状产生实质性影响1
  • 需要系统评估精神科副作用，包括情绪障碍、焦虑加重的可能1

具体监测内容

每次随访应评估1:

疗效评估

  • ADHD核心症状（注意力不集中、多动冲动）的改善
  • 焦虑和抑郁症状的变化
  • 功能改善情况（工作、学习、人际关系）

副作用监测

  • 常见副作用：食欲下降、失眠、头痛、焦虑加重1
  • 体格检查：体重、血压、脉搏1
  • 精神症状：情绪变化、焦虑恶化、自杀意念（特别重要，因为患者有抑郁）1

维持期随访

症状稳定后1:

  • 至少每月随访一次，直到症状完全稳定
  • 随访频率取决于：药物反应的稳健性、服药依从性、副作用问题、共病精神障碍的严重程度
  • 对于合并焦虑抑郁的患者，即使ADHD症状改善，仍需持续监测情绪症状

重要注意事项

剂量调整

  • 20mg Vyvanse是一个较低的起始剂量
  • 如果症状控制不佳，可在每周增加剂量2
  • 成人常用有效剂量范围为30-70mg3, 4

起效时间

  • Vyvanse通常在用药后1周内即可观察到显著改善4
  • 但完全疗效可能需要更长时间才能显现

共病管理的关键决策点

如果1周后评估发现：

  • ADHD症状改善但焦虑抑郁持续：考虑加用心理治疗或抗抑郁药1
  • 焦虑抑郁加重：需要重新评估治疗方案，可能需要先处理情绪症状
  • 两者均改善：继续当前治疗方案，逐步延长随访间隔

这种密集的早期监测对于合并精神障碍的患者尤为重要，可以及时发现问题并调整治疗方案，最大限度地改善患者的功能和生活质量。

References

1
Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Related Questions

What is the optimal adult dose of Vyvanse (lisdexamfetamine) for ADHD?
Can an adult with ADHD who is taking lisdexamfetamine (Vyvanse) at a standard dose safely take inositol (2–4 g daily)?
In a 40‑year‑old man taking lisdexamfetamine (Vyvanse) 30 mg daily who experiences marked anxiety/hyperarousal for the first three hours after dosing and then minimal therapeutic effect thereafter, what management steps are recommended?
In a 42-year-old male smoker taking Vyvanse (lisdexamfetamine) for ADHD who has unintentionally lost 6 pounds over two months, should this weight loss be concerning?
A 39-year-old woman with a history of ADHD treated with Vyvanse (lisdexamfetamine) in childhood needs medication now; what is the appropriate adult starting dose?
Should permethrin 5% lotion be applied once in the morning and once at night for scabies treatment?
In a patient with Crohn’s disease and seropositive rheumatoid arthritis who has an active oral infection requiring four tooth extractions and a gum lump, should methotrexate be started now, or should the infection be treated first, and what is the appropriate management?
In a patient with hypoalbuminemia, how can we ensure ertapenem remains protein‑bound rather than free?
Why does ertapenem become subtherapeutic in patients with hypoalbuminemia?
In a patient with AST (SGOT) and ALT (SGPT) levels ten times the upper limit of normal, what antiretroviral therapy should be used and how should it be managed?
What are the clinical features of Pierre Robin syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.